437 related articles for article (PubMed ID: 9435906)
1. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
2. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
4. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
[TBL] [Abstract][Full Text] [Related]
5. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
7. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
Silver PJ; Dundore RL; Bode DC; de Garavilla L; Buchholz RA; van Aller G; Hamel LT; Bacon E; Singh B; Lesher GY
J Pharmacol Exp Ther; 1994 Dec; 271(3):1143-9. PubMed ID: 7996419
[TBL] [Abstract][Full Text] [Related]
8. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
[TBL] [Abstract][Full Text] [Related]
9. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
10. Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs.
Kapui Z; Schaeffer P; Mikus EG; Boronkay E; Gyürky J; Herbert JM; Pascal M
Arzneimittelforschung; 1999 Aug; 49(8):685-93. PubMed ID: 10483515
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
[TBL] [Abstract][Full Text] [Related]
12. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
[TBL] [Abstract][Full Text] [Related]
13. A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
Allerton CM; Barber CG; Beaumont KC; Brown DG; Cole SM; Ellis D; Lane CA; Maw GN; Mount NM; Rawson DJ; Robinson CM; Street SD; Summerhill NW
J Med Chem; 2006 Jun; 49(12):3581-94. PubMed ID: 16759100
[TBL] [Abstract][Full Text] [Related]
14. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors.
Jiang W; Alford VC; Qiu Y; Bhattacharjee S; John TM; Haynes-Johnson D; Kraft PJ; Lundeen SG; Sui Z
Bioorg Med Chem; 2004 Mar; 12(6):1505-15. PubMed ID: 15018924
[TBL] [Abstract][Full Text] [Related]
16. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
